Distinguished Group of Dermatologists to Advise on Advancing the Company's
Pipeline
BOTHELL, Wash., Feb. 20 /PRNewswire-FirstCall/ -- Helix BioMedix, Inc.
(OTC Bulletin Board: HXBM), a developer of bioactive peptides, today
announced the creation of a Dermatology Scientific Advisory Board to
provide advice on scientific, clinical, and regulatory matters regarding
the company's patented peptide technology as it applies to the cosmetic
care and therapeutic treatment of the skin.
Joining Lori Bush, Chief Operating Officer and Dr. Timothy Falla, Chief
Scientific Officer of Helix BioMedix are three distinguished and
accomplished dermatologists who maintain clinical practices while
contributing to the body of scientific research that is advancing the
treatment of skin. Helix BioMedix's independent advisors include Dr. Zoe
Diana Draelos, Dr. Barbara Gilchrest and Dr. Mark Lebwohl.
"We are very pleased to have assembled this team of knowledgeable and
highly respected professionals to share their expertise and offer guidance
as part of our Scientific Advisory Board," said R. Stephen Beatty,
President and Chief Executive Officer. "During the past year, Helix
BioMedix has made numerous advancements in the development of our
cosmeceutical and pharmaceutical peptide technologies, particularly in the
areas of anti-aging skin care, acne treatment and management of a variety
of dermatoses. The extensive scientific and medical expertise of this Board
should prove invaluable as we move technology from laboratory to clinical
development. We are privileged to have each of these individuals associated
with Helix BioMedix."
Dermatology Scientific Advisory Board Members:
Lori Bush, Chief Operating Officer of Helix BioMedix. Ms. Bush is a 25
year veteran of the medical and consumer health and beauty industries.
Prior to joining Helix in October 2006 she was President of Nu Skin, the
multi-national personal care products division of Nu Skin Enterprises. As a
member of their executive committee, Ms. Bush was instrumental in
developing Nu Skin Enterprises' growth strategy while strengthening core
competencies in the areas of marketing and product development. Ms. Bush
also held several leadership positions within the skin care franchises of
the Johnson & Johnson Consumer Products Companies. In her role as Helix
BioMedix's COO, Ms. Bush employs her expertise in the commercialization of
the company's skin care peptides.
Dr. Zoe Diana Draelos, Clinical Associate Professor of Dermatology,
Wake Forest University School of Medicine. Dr. Draelos is the author of the
textbook Cosmetics in Dermatology, now in it second edition, and has
contributed chapters on cosmetics in 23 textbooks, writing 260 published
papers, and currently serving on five journal editorial boards. She is the
editor of The Journal of Cosmetic Dermatology and founded Dermatology
Consulting Services to provide education, perform adverse reaction
evaluation, and conduct clinical studies in association with the industry.
Dr. Barbara Gilchrest, Professor and Chair, Department of Dermatology
at Boston University School of Medicine and Chief of Dermatology at the
Boston Medical Center (BMC). A Harvard Medical School graduate, Dr.
Gilchrest is board certified in Internal Medicine and Dermatology. She is
the author or editor of 11 books on skin aging, photo aging, and UV effects
on skin and author of over 400 original articles, reviews, editorials, and
invited textbook chapters. She is a section editor for the Journal of
Investigative Dermatology, the leading research journal in the field, and
serves on the editorial board of 5 other dermatology or aging journals. Her
current research interests range from the molecular basis of skin aging to
DNA damage responses in skin to clinical studies of photodynamic therapy
for the prevention and treatment of photocarcinogenesis. Dr. Gilchrest is a
member of the Institute of Medicine of the National Academies of Science.
Timothy Falla, Ph.D., Vice President and Chief Scientific Officer of
Helix BioMedix. Dr. Falla joined the Company as Chief Scientific Officer in
June 2001 and is responsible for developing the Company's science and
technology and for its application to clinical and non-clinical product
candidates. Prior to joining the Company, Dr. Falla was employed by
IntraBiotics Pharmaceuticals, Inc., a biopharmaceutical company, where, as
principal scientist he led a multi-disciplinary research team focused on
antibacterial drug discovery and development. Prior to his tenure with
IntraBiotics, Dr. Falla held research associate positions at the University
of British Columbia and The Antimicrobial Research Centre at the University
of Leeds. Dr. Falla's work in the areas of infectious disease and peptide
development has been described in over 70 published papers, book chapters
and reviews.
Dr. Mark Lebwohl, Professor and Chairman, Department of Dermatology at
Mount Sinai School of Medicine. Dr. Lebwohl is past president of the New
York State Society of Dermatology and immediate past-chairman of the
Psoriasis Task Force of the American Academy of Dermatology. He is also a
member of the medical advisory board of the National Psoriasis Foundation
and editor of Psoriasis Forum and Psoriasis Advance, the patient bulletin
of the National Psoriasis Foundation. He is the "Medical Pearl" feature
editor and as well as assistant editor of The Journal of the American
Academy of Dermatology. Dr. Lebwohl has written several books on
dermatology, authored or co-authored over 400 publications and is actively
involved in clinical trials of new dermatological treatments.
About Helix BioMedix
Helix BioMedix, Inc. is a biopharmaceutical company that has a
portfolio of issued patents that covers six distinct classes of peptides,
covering over 100,000 unique peptide sequences. The company's mission is to
become the industry leader in developing and commercializing small proteins
known as bioactive peptides. The antimicrobial and wound healing properties
of these peptides qualify them for inclusion in a wide range of both
pharmaceutical and consumer products. The company is currently focused on
the development of selected peptides as topical anti-infectives and in
wound healing. Non-pharmaceutical applications being pursued by Helix
BioMedix include adjuvants for cosmetics/cosmeceuticals, personal care,
plant health, animal health and wide-spectrum biocides. More information
about the company and its proprietary peptides can be found on the
company's website at http://www.helixbiomedix.com .
Important Notice
This press release contains forward-looking statements (statements
which are not historical facts) within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking statements
include statements regarding activities, events or developments that the
company expects, believes or anticipates may occur in the future, including
statements related to our potential growth, product development and
commercialization and revenue. A number of factors could cause actual
results to differ from those indicated in the forward-looking statements,
including the company's ability to successfully raise additional capital,
enter into revenue generating license agreements, continue its research and
development efforts, including pre-clinical and clinical studies, and
general economic conditions. Additional assumptions, risks and
uncertainties are described in detail in our reports and other filings with
the Securities and Exchange Commission. Such filings are available on our
website or at http://www.sec.gov . Readers are cautioned that such forward-looking
statements are not guarantees of future performance and that actual results
or developments may differ materially from those set forth in the
forward-looking statements. The company undertakes no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances.
Contact:
Investor Relations:
Cameron Associates
Alison Ziegler, 212-554-5469
alison@cameronassoc.com
SOURCE Helix BioMedix, Inc.
 back to top
Related links:
http://www.helixbiomedix.com
CONTACT:
investors, Alison Ziegler of Cameron
Associates, +1-212-554-5469, or alison@cameronassoc.com, for
Helix BioMedix, Inc.
|
